Kooij Louise Frederika sold $3.2M of NAMS
Kooij Louise Frederika (Chief Accounting Officer) sold 105,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at an average of $30.34 ($29.96–$31.71, $3.19M total) across 3 trades on 2026-07-20 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale amount and execution details (105,000 shares, ~$3.19M) under a pre-arranged 10b5-1 plan; it does not include new guidance, trial results, or regulatory outcomes.
Market read
Traders may monitor insider activity for sentiment, but 10b5-1 sales generally have limited fundamental implications.
What to watch
The filing does not reveal whether other insiders or the company simultaneously bought shares, nor does it provide context on compensation, taxes, or diversification needs.
Background
The article is an SEC Form 4 insider transaction disclosure for NewAmsterdam Pharma Co N.V. (NAMS).
Ticker impact
Form 4 shows CFO Kooij Louise Frederika sold 105,000 shares of NAMS for about $3.19M under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven and typically short-lived for 10b5-1 sales.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company fundamentals, guidance, or regulatory/contract developments.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated; transaction is not tied to broader regional macro or policy.
None indicated; no cross-border deal, trial, or regulatory action is described.
Counterpoint
The sale may be purely liquidity-driven and consistent with planned 10b5-1 selling, so it should not be over-weighted as a bearish signal.
Key entities
- issuerNewAmsterdam Pharma Co N.V.
Subject of the Form 4 insider transaction disclosure.
- insiderKooij Louise Frederika
Chief Accounting Officer who sold shares under a 10b5-1 plan.
